Search Results
The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLL
Testing for IgHV and TP53 mutations to guide treatment decisions in CLL
The impact of IGHV mutational status in treatment decisions in CLL
The prognostic value of IgHV mutational status with continuous vs time-limited therapy in CLL
Important prognostic factors to evaluate in CLL patients in the era of small molecules
Relevance of current prognostication and prediction markers for CLL with new targeted therapies
Case 3: An Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Disease characteristics impacting treatment decisions in CLL
Impact of Prognostic Factors on Clinical Decisions in CLL
How Do Genetic Mutations Impact a CLL Patient’s Prognosis?
The impact of TP53 mutation on treatment approaches in MCL
